Use of licensed vaccines for active immunization of the immunocompromised host

Liise-anne Pirofski, Arturo Casadevall

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

The latter part of the 20th century has witnessed an unprecedented rise in the number of individuals with impaired immunity. This is primarily attributable to the increases development and use of antineoplastic therapy for malignancies, organ and bone marrow transplantation, and the AIDS epidemic. Individuals with impaired immunity are often at increased risk for infections, and they can experience more severe and complicated courses of infection. The lack of therapy for a variety of viruses and the rise in antimicrobial resistance of many pathogens have focused attention on vaccination to prevent infectious diseases. The efficacy of most licensed vaccines has been established in immunocompetent hosts. However, there is also considerable experience with most vaccines in those with impaired immunity. We reviewed the use of licensed live, inactivated, and polysaccharide vaccines in this group, and several themes emerged: (i) most vaccines are less immunogenic in those with impaired immunity than in normal individuals; (ii) live vaccines are generally contraindicated in this group; and (iii) the efficacy of many commonly used vaccines has not been established in people with impaired immunity. This review suggests that for most vaccines there are little or no efficacy data in those with impaired immunity but their use in this patient group is generally safe.

Original languageEnglish (US)
Pages (from-to)1-26
Number of pages26
JournalClinical Microbiology Reviews
Volume11
Issue number1
StatePublished - Jan 1998

Fingerprint

Immunocompromised Host
Immunity
Vaccination
Vaccines
Inactivated Vaccines
Infection
Bone Marrow Transplantation
Antineoplastic Agents
Communicable Diseases
Polysaccharides
Acquired Immunodeficiency Syndrome
Viruses
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Microbiology

Cite this

Use of licensed vaccines for active immunization of the immunocompromised host. / Pirofski, Liise-anne; Casadevall, Arturo.

In: Clinical Microbiology Reviews, Vol. 11, No. 1, 01.1998, p. 1-26.

Research output: Contribution to journalArticle

@article{897c2ed95da64ff78428d1dac322be24,
title = "Use of licensed vaccines for active immunization of the immunocompromised host",
abstract = "The latter part of the 20th century has witnessed an unprecedented rise in the number of individuals with impaired immunity. This is primarily attributable to the increases development and use of antineoplastic therapy for malignancies, organ and bone marrow transplantation, and the AIDS epidemic. Individuals with impaired immunity are often at increased risk for infections, and they can experience more severe and complicated courses of infection. The lack of therapy for a variety of viruses and the rise in antimicrobial resistance of many pathogens have focused attention on vaccination to prevent infectious diseases. The efficacy of most licensed vaccines has been established in immunocompetent hosts. However, there is also considerable experience with most vaccines in those with impaired immunity. We reviewed the use of licensed live, inactivated, and polysaccharide vaccines in this group, and several themes emerged: (i) most vaccines are less immunogenic in those with impaired immunity than in normal individuals; (ii) live vaccines are generally contraindicated in this group; and (iii) the efficacy of many commonly used vaccines has not been established in people with impaired immunity. This review suggests that for most vaccines there are little or no efficacy data in those with impaired immunity but their use in this patient group is generally safe.",
author = "Liise-anne Pirofski and Arturo Casadevall",
year = "1998",
month = "1",
language = "English (US)",
volume = "11",
pages = "1--26",
journal = "Clinical Microbiology Reviews",
issn = "0893-8512",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Use of licensed vaccines for active immunization of the immunocompromised host

AU - Pirofski, Liise-anne

AU - Casadevall, Arturo

PY - 1998/1

Y1 - 1998/1

N2 - The latter part of the 20th century has witnessed an unprecedented rise in the number of individuals with impaired immunity. This is primarily attributable to the increases development and use of antineoplastic therapy for malignancies, organ and bone marrow transplantation, and the AIDS epidemic. Individuals with impaired immunity are often at increased risk for infections, and they can experience more severe and complicated courses of infection. The lack of therapy for a variety of viruses and the rise in antimicrobial resistance of many pathogens have focused attention on vaccination to prevent infectious diseases. The efficacy of most licensed vaccines has been established in immunocompetent hosts. However, there is also considerable experience with most vaccines in those with impaired immunity. We reviewed the use of licensed live, inactivated, and polysaccharide vaccines in this group, and several themes emerged: (i) most vaccines are less immunogenic in those with impaired immunity than in normal individuals; (ii) live vaccines are generally contraindicated in this group; and (iii) the efficacy of many commonly used vaccines has not been established in people with impaired immunity. This review suggests that for most vaccines there are little or no efficacy data in those with impaired immunity but their use in this patient group is generally safe.

AB - The latter part of the 20th century has witnessed an unprecedented rise in the number of individuals with impaired immunity. This is primarily attributable to the increases development and use of antineoplastic therapy for malignancies, organ and bone marrow transplantation, and the AIDS epidemic. Individuals with impaired immunity are often at increased risk for infections, and they can experience more severe and complicated courses of infection. The lack of therapy for a variety of viruses and the rise in antimicrobial resistance of many pathogens have focused attention on vaccination to prevent infectious diseases. The efficacy of most licensed vaccines has been established in immunocompetent hosts. However, there is also considerable experience with most vaccines in those with impaired immunity. We reviewed the use of licensed live, inactivated, and polysaccharide vaccines in this group, and several themes emerged: (i) most vaccines are less immunogenic in those with impaired immunity than in normal individuals; (ii) live vaccines are generally contraindicated in this group; and (iii) the efficacy of many commonly used vaccines has not been established in people with impaired immunity. This review suggests that for most vaccines there are little or no efficacy data in those with impaired immunity but their use in this patient group is generally safe.

UR - http://www.scopus.com/inward/record.url?scp=0031984194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031984194&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 1

EP - 26

JO - Clinical Microbiology Reviews

JF - Clinical Microbiology Reviews

SN - 0893-8512

IS - 1

ER -